Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pelthos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pelthos Therapeutics's position in the market.
Pelthos Therapeutics (NYSE American: PTHS) signed its first commercial agreement to expand patient access to ZELSUVMI™ (berdazimer) topical gel, 10.3%, an FDA‑approved at‑home treatment for molluscum contagiosum. The company entered a deal via a Group Purchasing Organization with a pharmacy benefit manager that covers more than 20 million lives; formulary inclusion updates began on December 1, 2025. ZELSUVMI launched in July 2025, is approved for patients aged one year and older, and received a Novel Drug designation from FDA in January 2024. Pelthos says the PBM partnership aims to improve coverage, distribution, and patient access to the once‑daily topical gel.
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 at 9:30 a.m. ET at The Lotte New York Palace, 455 Madison Avenue, New York.
Institutional investors can request in-person one-on-one meetings via their Piper Sandler representative. A live webcast of the fireside chat will be available on the company’s Investors News & Events page and posted at the event webcast link approximately two hours after the presentation.
Pelthos Therapeutics (NYSE American: PTHS) reported third quarter fiscal 2025 results on November 13, 2025, following its merger and equity raise. Key commercial and corporate actions include a July 2025 launch of ZELSUVMI (first FDA-approved at‑home molluscum contagiosum treatment) that generated $7.1 million in net revenues with 2,716 units dispensed by 1,169 prescribers in Q3. The company closed a $50.1 million private placement, completed the XEPI acquisition in November 2025, and closed an $18 million convertible notes financing. Cash as of September 30, 2025 was $14.2 million.
Pelthos Therapeutics (NYSE: PTHS) acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1% and closed an $18 million private convertible notes financing on Nov 7, 2025. Pelthos paid $3.0M to Biofrontera and $1.2M to Ferrer upfront, with additional sales‑based milestones and royalties payable. Xepi is FDA‑approved for impetigo in patients two months and older; Pelthos plans a re‑launch in late 2026. The Notes bear 8.5% interest, mature Nov 6, 2027, and convert at an initial price of $34.442. Proceeds will fund the Xepi relaunch, commercial acceleration of ZELSUVMI, and working capital.
Pelthos Therapeutics (NYSE American: PTHS) will report third quarter 2025 financial results and host a conference call on Thursday, November 13, 2025 at 8:00 a.m. Eastern Time.
The company said a press release with financial results will be issued prior to the call. Management will discuss results for the quarter ended September 30, 2025, followed by a Q&A session. Dial-in details: toll-free 1-877-451-6152, international 1-201-389-0879, Conference ID 13756828. A live webcast will be available at the provided webcast URL.
Pelthos Therapeutics (NYSE: PTHS) on Oct 9, 2025 launched the Moms Against Molluscum movement and MomsAgainstMolluscum.com to unite families affected by molluscum contagiosum and share resources.
The company highlights its prescription topical ZELSUVMI (berdazimer) 10.3% gel, launched in July 2025 and described as a once-daily, at-home nitric oxide-releasing treatment. ZELSUVMI received a Novel Drug designation from the FDA in Jan 2024. The release cites disease burden: an estimated 16.7 million Americans affected and up to 6 million new U.S. incidents annually, mostly children.
Pelthos Therapeutics (NYSE American: PTHS) announced its participation in two upcoming investor conferences in September 2025. The company's CEO Scott Plesha and CFO Frank Knuettel II will represent Pelthos at the H.C. Wainwright 27th Annual Global Investment Conference in New York City and the Investor Summit Group Q3 Virtual Conference.
At the H.C. Wainwright conference, scheduled for September 8-10, 2025, management will deliver a presentation on September 10 at 10:30 A.M. ET and will be available for one-on-one meetings. The virtual Investor Summit Group conference will take place on September 16-17, 2025. A webcast of the H.C. Wainwright presentation will be available on Pelthos' website with a 90-day replay period.
Pelthos Therapeutics (NYSE American: PTHS), a biopharmaceutical company, announced its participation in the upcoming Wells Fargo Healthcare Conference. CEO Scott Plesha and CFO Frank Knuettel will deliver a presentation on Wednesday, September 3rd, 2025 at 1:30 p.m. ET.
The presentation will be accessible via webcast on the Events and Presentations section of Pelthos' website, with replays available for 90 days following the event. Institutional investors interested in one-on-one meetings should contact their sales representatives.
Pelthos Therapeutics (NYSE American: PTHS) reported Q2 2025 financial results and significant business developments. The company completed a merger with Channel Therapeutics and secured a $50.1 million private placement financing led by Murchinson Ltd. on July 1, 2025.
Key highlights include the successful launch of ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum, targeting a market of 16.7 million affected people with up to 6 million new cases annually in the US. The company has expanded its infrastructure, hiring 50 territory sales managers and growing to over 90 employees. The company's current market cap is approximately $55 million, with an implied value of $165 million post-conversion of Series A Preferred Stock.
Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, marking a significant milestone as the first and only FDA-approved at-home treatment for molluscum contagiosum. The novel nitric oxide-releasing gel, which received FDA Novel Drug designation in January 2024, is now commercially available through prescription.
In Phase 3 clinical trials involving 891 patients, ZELSUVMI demonstrated complete clearance in 33% of patients compared to 19.7% in the control group at week 12, with some patients showing results within two weeks. The treatment targets an estimated 16.7 million affected people in the United States, with up to 6 million new cases annually.
To support the launch, Pelthos has deployed 50 sales territory managers nationwide and implemented the ZelsuvmiGo patient support program to facilitate patient access and education.
FAQ
What is the current stock price of Pelthos Therapeutics (PTHS)?
What is the market cap of Pelthos Therapeutics (PTHS)?
